Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT05492578) titled 'Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials' on Aug. 5, 2022.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sanofi
Condition:
Dermatitis Atopic
Intervention:
Drug: Amlitelimab
Drug: Topical corticosteroids
Drug: Topical calcineurin inhibitors
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: August 22, 2022
Target Sample Size: 1551
Countries o...